Apart from validating the canonical pro-proliferative and pro-metastatic functions of PAK1, we have characterized a hitherto undescribed PAK1/STAT5B/CSF2 regulatory axis in myxofibrosarcomas, wherein the pro-angiogenic attribute of PAK1 offers a viable molecular target to inform risk stratification and therapeutic strategies. Here, CSF2 is linked to myxofibrosarcoma.